Clinical trial
A Phase 2 Multi-Center, Open-Label, Switch-Over Trial to Evaluate the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase
NCT02053896 is registered in ClinicalTrials.gov with ISU Abxis Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multi-Center, Open-Label, Switch-Over Trial to Evaluate the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase
- Lead sponsor
- ISU Abxis Co., Ltd.
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2011
- Completion date
- February 29, 2012
- Enrollment
- 5 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.